Trial Profile
Randomised, double-blind, double-dummy, multicentre study to compare the efficacy and safety of once daily novel 4 mg budesonide suppository versus once daily 2 mg budesonide foam in patients with acute ulcerative proctitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2021
Price :
$35
*
At a glance
- Drugs Budesonide (Primary) ; Budesonide
- Indications Ulcerative proctitis
- Focus Therapeutic Use
- Sponsors Dr Falk Pharma
- 23 May 2021 Primary endpoint (Rate of mucosal healing) has been met. according to the results presented at the Digestive Disease Week 2021.
- 23 May 2021 Primary endpoint (Rate of clinical remission) has been met. according to the results presented at the Digestive Disease Week 2021.
- 23 May 2021 Results assessing the efficacy and safety of budesonide 4 mg suppositories (BUS) vs. budesonide 2 mg rectal foam (BUF) in patients with acute ulcerative proctitis, presented at the Digestive Disease Week 2021